Due to the fact Pirfenidone is metabolised in the CYP1A2 enzyme pathway, any drug which inhibits this enzyme is probably going to precipitate the toxicity of pirfenidone: concomitant therapy is usually to be prevented. Supplemental monitoring and dosage adjustment could be required in accordance with product labeling of CYP1A2 substrates. https://actors998fpa1.wikiexpression.com/user